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John G. Gribben,1 Chitra Hosing,2 David G. Maloney3The indolent lymphomas, including chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) remain
incurable with standard therapy. Autologous hematopoietic stem cell transplantation (HSCT) is feasible and
has low treatment-related mortality in follicular lymphoma, but there are questions relating to optimal timing
of the procedure, conditioning regimen, and late effects. Myeloablative allogeneic HSCT is associated with
high treatment-related morbidity and mortality, few late relapses, but is applicable to only a small number
of patients. The major focus of HSCT in these lymphomas has been with reduced-intensity conditioning
(RIC) allogeneic HSCT, which is applicable to the age distribution of these diseases and which exploits the
graft-versus-lymphoma effect in these diseases. Steps to further decrease the morbidity and mortality of
the RIC HSCT and in particular to reduce the incidence of chronic extensive graft-versus-host disease
(GVHD) while maintaining tumor control remain the major focus. Many potential treatments are available
for indolent lymphomas and CLL, and appropriate patient selection and the timing of HSCTremain contro-
versial. The use of HSCT must always be weighed against the risk of the underlying disease, particularly in
a setting where improvements in treatment are leading to improved outcome.
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Hematopoietic stem cell transplantation (HSCT)
has become the treatment of choice for patients with
relapsed aggressive non-Hodgkin lymphoma (NHL)
and Hodgkin lymphoma (HL). To date, most of these
patients have been treated with autologous stem cells,
currently usingperipheral blood stemcells (PBSCs)mo-
bilized by chemotherapy and/or recombinant growth
factors. The role of HSCT in the management of
patients with indolent lymphoma remains more contro-
versial, although increasing numbers of patients with
advanced-stage follicular lymphoma, mantle cell lym-
phoma, and chronic lymphocytic leukemia are now
undergoing HSCT. There is increasing concern1Barts and The London School of Medicine, London,
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autologous HSCT, especially if done late in high-risk
patients and, in the long-term, toxicity associated with
this approach, especially the development of secondary
myelodysplastic syndrome and other cancers. This has
led to renewed interest in the role of allogeneic HSCT
for patients with indolent lymphoma, although major
problems remain with the high treatment-related mor-
tality (TRM) associated with myeloablative allogeneic
HSCT as well as graft-versus-host disease (GVHD).
The advantage of allogeneic HSCT is the potential to
exploit the graft-versus-lymphoma/leukemia (GVL)
effect. Many studies are underway exploring the use of
reduced-intensity conditioning (RIC) regimens, steps
to control disease progression and manipulate donor
cells to maximize T cell responsiveness against lym-
phoma and minimize GVHD.Patient Selection
Unlike aggressive lymphomas, the use of high-
dose chemotherapy with autologous HSCT in the
treatment of indolent lymphomas has not yet been
fully established. The rationale for considering trans-
plantation is that the disease is incurable using stan-
dard approaches and that younger patients with these
‘‘indolent lymphomas’’ will die of their disease, and
that promising results have been observed in a number
of phase II studies [1-3]. Detection of minimal residualS63
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tracking long-term progression-free survival (PFS) in
patients, in examining tumor contamination of autolo-
gous stem cells, and in monitoring serial samples after
transplantation [3-7]. A major concern relates to the
risk of development of secondary myelodysplasia/
acute myeloid leukemia, especially with the use of
high-dose total-body irradiation (TBI)-containing
conditioning regimens [8]. The role of high-dose
therapy and autologous HSCT in FL follicular
lymphoma (FL) patients during first remission has
been explored in phase II trials [9,10], and in 4 phase
III randomized trials [11-14]. Three hundred seven
previously untreated patients, up to 60 years of age
who responded to induction chemotherapy, were
randomized to autologous HSCT or interferon
(IFN)-a maintenance [11]. Among 240 evaluable pa-
tients, the 5-year PFS was 64.7% for autologous
HSCT, and 33.3% in the IFN-a arm (P \ .0001).
Acute toxicity was higher in the autologous HSCT
group, but early mortality was\2.5% in both study
arms. One hundred seventy-two newly diagnosed ad-
vanced FL patients were randomized to combination
chemotherapy and IFN-a or to high-dose therapy fol-
lowed by purged autologous HSCT [12]. Patients
treated with autologous HSCT had a higher response
rate than patients who received chemotherapy and
IFN-a (81% versus 69%, P 5 .045) and a longer me-
dian PFS (not reached versus 45 months), but this
did not translate into a better overall survival (OS) be-
cause of an excess of secondary malignancies after
transplantation. Four hundred one previously un-
treated advanced-stage FL patients were randomized
to receive combination chemotherapy and IFN-a com-
pared with 4 courses of CHOP chemotherapy fol-
lowed by high-dose therapy using TBI and
autologous HSCT. Intent-to-treat analysis after a me-
dian follow-up of 7.5 years showed no difference
between the 2 arms for OS (P 5 0.53) or PFS (P 5
0.11). Long-term follow-up demonstrated no statisti-
cally significant benefit in favor of first-line ASCT in
patients with FL. Only 1 study used rituximab-
containing chemoimmunotherapy (CHOP-R) [14].
Patients relapsing after CHOP-R underwent salvage
therapy with autologous HSCT. No OS advantage
was seen for high-dose therapy. In view of these
results, autologous HSCT should be used in first
remission only in the setting of clinical trials.
The European Bone Marrow Transplant (EBMT)
Registry–sponsored CUP (conventional Chemother-
apy, Unpurged, Purged autograft) study is the only
prospective randomized trial to assess the role of autol-
ogous HSCT in patients with relapsed FL [15]. The
results of the study suggest a PFS and OS advantage
of ASCT over conventional chemotherapy, with
4-year OS of 46% for the chemotherapy arm, versus
71% for the unpurged and 77% for the purgedASCT arms. The study was closed early because of
slow accrual with 140 of the planned 250 patients ac-
crued and only 89 randomized. In chronic lymphocytic
leukemia/snall lymphocytic leukemia (CLL/SLL), the
use of HSCT was not associated with improved out-
come in patients transplanted in first remission com-
pared to those transplanted later in their disease
course [16].
Autologous HSCT is not a suitable treatment op-
tion for most patients with CLL. The disease usually
follows an indolent course; many patients never re-
quire any therapy, and most patients are too elderly
to undergo this procedure. In addition, treatment
with fludarabine or other purine analogues makes
collection of autologous peripheral blood stem cell
(PBSC) difficult, and tumor cell contamination of the
bone marrow is high. High-risk patients can be identi-
fied using a number of clinical and biologic features,
and such younger patients are suitable candidates for
enrolment in clinical trials evaluating the role of
HSCT in CLL. The role of HSCT has been estab-
lished in prospective studies in a number of other
hematologic malignancies, but no studies in CLL pub-
lished to date have compared the outcome after
standard chemotherapy with either autologous or allo-
geneic HSCT. Using clinical and biologic features, it
is possible to identify patients who are suitable candi-
dates for enrolment in clinical trials evaluating the
role of HSCT. The biggest challenges remain the de-
cision of which patients are eligible for consideration
of HSCT and when in their disease course HSCT
should be offered.
No studies have prospectively compared the role of
standard chemotherapy with autologous HSCT in
CLL, and there is no established role for this approach
except in the setting of a clinical trial. A retrospective
matched-pair analysis has suggested a survival advan-
tage for autologousHSCTcomparedwith conventional
therapy [17]. This used a risk-matched comparison
between 66 patients who had undergone a uniform
high-dose therapy and autologous HSCT with a data-
base of 291 patients treated conventionally. Matched
data included age, Binet stage, IgVH mutational status,
and lymphocyte count, and 44 patient pairs matched
all 4 variables. With an overall median follow-up
time of 70 and 86 months, survival was significantly
longer for the patients who had undergone autologous
HSCT compared with conventionally treated patients
when calculated from diagnosis (P5 .03) or from study
entry (P 5 .006).
A number of phase II studies have reported
outcome after autologous HSCT for CLL [18-20].
These studies have demonstrated that this approach
is feasible in CLL with a TRM of 1% to 10%, with
most toxicity occurring late. Among 115 previously
untreated CLL patients prospectively enrolled in
a pilot study to assess the feasibility of performing
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transplant [19]. Only 1 TRM was seen, and the com-
plete remission (CR) rate after transplantation was
74% (48 of 65). The 5-year estimated OS was 77.5%
and PFS was 51.5%. None of the variables examined
at study entry were predictive for OS or PFS, but de-
tectable MRD was highly predictive of disease recur-
rence. Most studies reported have relatively short
follow-up and therefore focus only on TRM early
post-transplant, but late consequences also occur, par-
ticularly development of secondary myelodysplasia
and acute myeloid leukemia (MDS/AML) and a high
incidence of development of other solid tumors [18].Myeloablative Allogeneic HSCT
Allogeneic transplantation was initially pioneered
for the treatment of acute and chronic leukemias,
and patients with indolent lymphoma were seldom of-
fered this approach. There were excellent outcomes
following autologous HSCT in phase II studies, and
in a small randomized clinical trial, a clinical benefit
was seen for auto-SCT over conventional chemother-
apy in FL [15]. Studies of MRD showed a strong asso-
ciation between lymphomatous involvement of the
autologous graft and disease recurrence [4]. This pro-
vided the initial rationale for myeloablative allogeneic
HSCT, which was initially used in patients with exten-
sive marrow involvement or those who had failed
previous auto-HSCT. TBI-containing regimens were
largely used and the results of selected studies are
shown in Table 1. An International Bone Marrow
Transplantation Registry (IBMTR) analysis of 113
patients reported over a 12-year period (1984-1995)
by 50 teams worldwide, an average of 2 patients per
team [21]. The registry analysis confirmed a very
high rate of durable disease control after allogeneic
HSCT for indolent lymphoma and only a 16% inci-
dence of disease recurrence. However, TRM was
high, and adverse outcome and high TRM were seen
in patients with refractory disease, decreased perfor-
mance status, or age over 40 years. Very similar results
were seen with EBMT registry analysis, which also
found similar OS and PFS formyeloablative allogeneic
HSCT [22]. In a case-control analysis they reported
less relapse after allogeneic compared to autologous
HSCT, but survival after allogeneic HSCT appearedTable 1. Selected Results of Myeloablative Allogeneic HSCT for In
N Conditioning
Age, Years
(Range)
HLA Sib/
Other Donor
Chemo-sensitive
Disease
120 TBI 75% non-TBI 25% 44 (22-70) 100% 72%
231 Various 39 (19-66) 96%/4% 80%
113 TBI 84% non-TBI 16% 38 (15-61) 199% 63%
TBI indicates total-body irridiation; GVHD, graft-versus-host disease; TRM, tre
topoietic stem cell transplantation.inferior because of the increased TRM. Data suggest
that the outcome of myeloablative transplant is
improving over time, most likely related to more judi-
cious patient selection as well as better supportive care
[23].
In CLL, allogeneic HSCT has significant morbid-
ity and mortality, from regimen-related toxicity,
GVHD, and infection, but surviving patients may
have long-term disease control [18,24-26]. In registry
data, TRM following allogeneic HSCT in CLL
patients was unacceptably high at 46%, with
mortality from GVHD of 20% [24]. Of 25 patients
with CLL who underwent allogeneic HSCT at the
Fred Hutchinson Cancer Center, grades 2-4 acute
GVHD (aGVHD) were seen in 14 patients, 10 devel-
oped clinical extensive chronic GVHD (cGVHD); and
estimated OS at 5 years was 32% [27]. Nonrelapse
mortality (NRM) at day 100 was unacceptably high
at 57% for patients conditioned with busulfan and
cyclophosphamide compared to 17% for patients con-
ditioned with TBI-containing regimens. Among 30
patients (20 related donors and 10 unrelated donors)
transplanted for CLL between 1989 and 2001 in Van-
couver with a median follow-up of 4.3 years, 47%were
alive in CR, both estimated OS and DFS at 5 years
were 39%. A strong GVL effect was noted, with
those developing aGVHD or cGVHD having near
complete protection from relapse.
There are no randomized studies comparing the
outcome of autologous versus allogeneic HSCT. In
a report of the IBMTR, results are described for 904
patients with FL [27]. Among these patients, 176
patients underwent allogeneic HSCT, 131 patients
underwent autologous HSCT using purged stem cells,
and 597 using unpurged autologous stem cells. The
TRM in these 3 groups was 30%, 14%, and 8%
respectively, disease recurrence was 21%, 43%, and
58%, and 5-year overall survival was 51%, 62%, and
55%, respectively. The use of TBI-containing regi-
mens was associated with increased TRM, but de-
creased risk of relapse. The use of allogeneic HSCT
was associated with increased TRM, but significantly
lower risk of disease recurrence, consistent with
GVL effect and possibly the use of a tumor-free stem
cell source. Further steps that decrease the TRM after
allogeneic HSCT are therefore likely to result in im-
proved outcome in these diseases, with resultingdolent Lymphoma
TRM %
Chronic
GVHD PFS % OS %
Median
F/U (mo) Reference
25 46% 67 71 50 Hari et al. 2008 [23]
38 — 43 51 60 Peniket et al. 2003 [22]
40 24% 49 49 36 Van Besien 1998 [21]
atement-related mortality; PFS, progression-free survival; HSCT, hema-
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with autologous HSCT, although long-term follow-
up will be required to confirm this. In CLL, studies
from M.D. Anderson Cancer Center demonstrate
improved outcome after allogeneic compared to autol-
ogous HSCT [28], suggesting that allogeneic HSCT
can induce durable remission even in patients with re-
fractory disease. At the Dana-Farber Cancer Institute,
162 patients with high-risk CLL were enrolled in
a ‘‘biologic randomization’’ in which 25 patients with
an HLA-matched sibling donor underwent T cell–
depleted myeloablative allogeneic HSCT, whereas
137 with no HLA-matched sibling donor underwent
B cell–purged autologousHSCT, with both groups re-
ceiving an identical conditioning regimen using high-
dose cyclophosphamide and TBI [18]. The 100-day
TRM was 4% after autologous or allogeneic HSCT,
but later TRM had a major impact on outcome. At the
median follow-up of 6.5 years, PFS was significantly
longer following autologous thanT cell–depleted allo-
geneic HSCT, but no significant differences were
observed in disease recurrence or deaths without re-
currence by type of transplant. There was no differ-
ence in OS between the 2 groups, and at the median
follow-up time of 6.5 years, OS was 58% after autolo-
gous and 55% after allogeneic HSCT.
RIC HSCT
A major advance in reducing the short-term mor-
bidity and mortality of allogeneic HSCT has been
the introduction of nonmyeloablative or RIC regimens
to allow engraftment of allogeneic stem cells. Most
patients to date have been treated on experimental
treatment protocols that allowed enrolment of many
patients with chemorefractory end-stage disease.
RIC regimens allow transplantation in older pa-
tients, making this approach more applicable to in-
creased numbers of patients. Results from the larger
reported studies in indolent lymphoma [23,29-32] are
shown in Table 2 and for CLL [33-38] in Table 3.
Most patients were heavily pretreated, and many wereTable 2. IC Allogeneic HSCT for FL
n
Age Years
(Range) Regimen
Chemo-
Refractory (%)
Prior
Auto
Donor (Rela
Unrelated
47 53 Flu/CY/Rit 0 — 96%
(33-68) 4%
62* 54 (Flu)/tbi 33% 26% 55%
(33-66) 45%
88 51 Various 31% — 100%
(21-70)
73 54 Flu/Bu/ATG 26% — 86%
(37-67) Various 14%
52 46 Various 15% — 91%
(27-65) 9%
GVHD indicates graft-versus-host disease; TRM, treatment-related mortality; P
ymocyte globulin; HSCT, hematopoietic stem cell transplantation.
*Sixteen had transformed.already refractory to therapy, but despite this, the ma-
jority demonstrated donor engraftment, and there was
a high CR rate. The ability of such approaches to erad-
icateMRD in patients with advanced CLL [39] and the
observation of late remissions in patients treated with
low doses of chemotherapy provide the strongest direct
evidence for a powerful GVL in CLL. The outcome
from the Fred Hutchinson Cancer Research Center
multi-institutional protocol after RIC allogeneic
HSCT for 82 patients with advanced fludarabine re-
fractory CLL using related (n 5 52) or unrelated do-
nors (n 5 30), median age 56 (range: 42-72) years,
demonstrated TRM of 23% at 5 years, with significant
GVHD remaining a problem [33]. Five-year OS
was 50%, and disease-free survival (DFS) was 39%. Al-
though complications were higher in the patients with
unrelated donors, there were higher CR and lower
relapse rates, suggesting more effective GVL activity
with unrelated donors. Forty-six patients underwent
RIC transplantation at Dana-Farber Cancer Institute,
67% using unrelated donors [35]. Factors associated
with increased risk of relapse include low levels of
donor chimerism at day 30, chemorefractory disease,
increased number of previous therapies, and adverse
cytogenetics [35].
The status of positron emission tomography
(PET) scan at HSCT does not appear to predict out-
come after reduced-intensity allogeneic HSCT [40].
This is in contrast with observations in autologous
HSCT, where outcome for patients with metabolic ev-
idence of residual lymphoma was significantly worse
than in patients with negative PET scans before trans-
plantation. These data suggest that RIC-HSCT is able
to overcome the unfavorable prognostic effects of
a positive PET before transplantation. AnyGVL effect
is most probable to be effective in the presence of rel-
atively low disease burden, and relapse should ideally
be detected early to maximize the benefit of RIC-
SCT or subsequent donor leukocyte infusion (DLI).
The use of PET surveillance after RIC-SCT was
able to detect early relapse that was not apparent onted/
) TRM
Chronic
GVHD Survival Reference
15% 60% OS 85% 5 yr Khouri et al. 2008 [29]
PFS 83%
42% 47% OS 52% 3 yr Reznavi et al. 2008 [30]
PFS 43%
28% 62% OS 62% 3 yr Hari et al. 2008 [23]
PFS 55%
15% 43% OS 55% 3 yr Vigouroux et al. 2007 [31]
PFS 53%
31% 17% OS 65% 1 yr Robinson et al. 2002 [32]
PFS 54%
FS, progression-free survival; Bu, busulfan; Flu, fludarabine; ATG, antith-
Table 3. RIC Allogeneic HSCT for CLL
N
Age Years
(Range)
Prior
Regimens
(Range)
Chemo-
Refractory
(%)
Prior
Auto-SCT
Donor
(Includes
Mismatch) TRM
GVHD
Acute
gd 2-4
Chronic
Extensive Survival Reference
82 82 4 87% 4 63% related 25% 55% 49% related OS 50% 5 yr Sorror et al. 2008 [33]
(42-72) 37% unrelated 53% unrelated PFS 45%
77 54 3 33% 10 81% related 18% 12 m 34% 58% OS 72% 2 yr Dreger et al. 2003 [34]
(30-66) (0-8) PFS 56%
46 53 5 57% 10 33% related 17% 34% 43% OS 54% 2 yr Brown et al. 2006 [35]
(35-67) (1-10) 67% unrelated PFS 34%
41 54 3 27% 11 58% related 5% at 100 d 10% 33%* OS 51 2 yr Delgado et al. 2006 [36]
(37-67) (1-8) 42% unrelated 26% (gd 3-4) PFS 45%
39 57 3 Not stated 90% related 2% at 100 d 45% 58% OS 48% 4 yr Khouri et al. 2006 [37]
(34-70) (2-8) 10% unrelated PFS 44%
30 50 3 47% 50% related 13% 56% 21% OS 72% 2 yr Schetelig et al. 2003 [38]
(12-63) (0-8) 50% unrelated PFS 67%
OS indicates overall survival; PFS, progression-free survival; DLI, donor leukocyte infusion; CLL, chronic lymphocytic leukemia; RIC, reduced-intensity
conditioning; HSCT, hematopoietic stem cell transplanataion.
*Includes after DLI.
Biol Blood Marrow Transplant 17:S63-S70, 2011 S67HSCT in Indolent Lymphomasimultaneous CT scans and can be used to direct the
use of DLI [40].
No formal assessment of RIC compared to mye-
loablative allogeneic HSCT has been undertaken in
a prospective trial. IBMTR compared traditional mye-
loablative allogeneic HSCT (n 5 120) to RIC-SCT
(n 5 88) in patients with follicular lymphoma trans-
planted with HLA-identical siblings between 1997
and 2002 [23]. As has been seen in many single-
center studies, patients receiving RIC tended to be
older and have a longer interval from diagnosis to
transplant. Themedian follow-up period aftermyeloa-
blative allogeneic HSCT was 50 months (4-96
months) compared with 35 months (4-82 months)
after RIC-SCT (P\ .001). At 3 years, OS was 71%
and PFS 67% for the myeloablative allogeneic
HSCT group, and for the RIC-SCT, OS was 62%
and PFS 55%. These differences were not significant.
Poor performance score and resistance to chemother-
apy were associated with higher TRM, and lower OS
and PFS. An increased risk of lymphoma progression
after RIC-SCT was observed in multivariate analysis
(relative risk 5 2.97, P 5 .04). Of interest, the use of
RIC regimens increased from 10% of transplants in
1997 to 80% in 2002, establishing RIC-SCT as a de
facto standard for allogeneic HSCT in patients with
indolent lymphoma. The differences in patient
selection (age, disease bulk, comorbid conditions) for
myeloablative versus RIC make it difficult to draw
conclusions regarding the role of high-dose versus
RIC and the effect of GVL immune activity.
For CLL patients, the outcome of 73 patients who
had undergone RIC was compared with that of 82
matched patients who had undergone standard myeloa-
blative allogeneic HSCT for CLL from the EBMT
registry database during the same time period. Patients
undergoing RIC-SCT had significantly reduced TRM,
but higher relapse incidence, and there was no
significant difference in OS or PFS between these 2
groups [41]. Of particular interest is the group of CLLpatients with deletion of 17p and loss of p53. A recent
report from EBMT of 44 such patients suggests that al-
logeneic HSCT has the potential to induce long-term
remission in these very high-risk patients [42].Addition of Monoclonal Antibodies to RIC
HSCT
GVHD remains the major concern after RIC-
HSCT, and attempts have been made to utilize mono-
clonal antibodies to reduce the incidence of GVHD
without increasing the subsequent risk of relapse.
Excellent results have been obtained using RIC based
on a combination of fludarabine, cyclophosphamide
with the addition of rituximab at the M.D. Anderson
Cancer Center, an approach designed to maximize
GVL by early tapering of immune suppression with
use of rituximab and DLI. Among 39 patients treated,
median age was 57 (range: 34-70) years, median time
from diagnosis to transplantation was 4.5 years [37].
All patients had recurrent advanced disease, were
heavily pretreated with a median of 3 (range: 2-8)
chemotherapy regimens, and all had been previously
treated with fludarabine-rituximab–based regimens.
At transplant, 34 patients (87%) had active disease,
including 9 (23%) with evidence of Richter’s transfor-
mation. In this series, only 4 of the donors were unre-
lated. Fourteen patients required immunomodulation
with rituximab and DLI for persistent disease after
HSCT. Only 1 patient died early, and among the 38
evaluable patients, 27 (71%) achieved CR, with an
estimated OS at 4 years of 48%, and current PFS of
44%. Acute grade II-IV GVHD was observed in
45%, but chronic extensive GVHD was reduced
without concomitant increased risk of relapse.
GVHD can also be decreased using alemtuzumab
in the conditioning regimen, but this delays post-SCT
immune reconstitution, increases the risk of infective
complications, and does appear to impair GVL. In 41
consecutive CLL patients treated (24 HLA-matched
S68 Biol Blood Marrow Transplant 17:S63-S70, 2011J. G. Gribben et al.sibling donors and 17 unrelated volunteer donors,
including 4 mismatched), the conditioning regimen
alemtuzumab with fludarabine and melphalan had sig-
nificant antitumor effects with 100% of patients with
chemosensitive disease and 86% with chemorefractory
disease responding [36]. The TRM rate was 26%, OS
51%, and relapse risk 29% at 2 years. GVHD rates
were relatively low with aGVHD occurring in 17
(41%) and cGVHD in 13 (33%). The unexpectedly
high TRM rate was because of a high incidence of
fungal and viral infections.Exploration of the GVL Effect in Lymphoma
Following RIC-SCT, the major antitumor effect is
from theGVLeffect.Currently, the targets of theGVL
effect andwhetherGVL can be separated fromGVHD
are not clear. Donor T cells can recognize host minor
histocompatibility antigens that may also be expressed
on the tumor cell. If this is thewhole basis ofGVL, then
the therapeutic window betweenGVLandGVHDwill
be very narrow. If donor T cells can also recognize
tumor-associated antigens in the host, theoretically
a GVL effect could occur without the major side effect
of GVHD and could therefore be exploited in a post-
transplant setting. Importantly, if this mechanism can
be maximized, it should be possible to induce using
autologous as well as allogeneic T cells. The outcome
in FL is strongly influenced by the immune cell micro-
environment [43-45], immune therapy including
monoclonal antibodies [46], therapeutic vaccines [47],
and rituximab, which surprisingly enhances immune re-
sponses against FL [48]. The mechanisms whereby the
immune microenvironment affects FL outcome is
poorly understood, but tumor cells alter antitumor im-
mune responses, including recruitment of pro-tumor
macrophages and suppression of cytolytic T cells
[49,50]. We have demonstrated that CLL cells induce
changes in autologous T cells and that coculture of
CLL cells with healthy allogeneic T cells can induce
similar defects [51]. The mechanism whereby tumor
cells impair cell function appears to bemediated at least
in part by actively impairing T cell actin cytoskeleton,
essential for activation and function [52]. We have
shown that FL-inducedTcell dysfunction in the lymph
node occurs by a similar mechanism [53], and that sub-
sets of infiltrating macrophages induce angiogenesis
[54]. These results define a novel immunosuppressive
mechanism induced by FL and CLL cells, and identify
functional tumor microenvironment biomarkers that
should facilitate development of enhanced immuno-
therapeutic strategies for lymphoma patients. The
question remains as to whether remaining tumor cells
in the host can also induce an immunosuppressive
effect on donor T cells at the time of RIC-SCT and
infusion of donor lymphocytes.We are currently exploring the molecular mecha-
nisms in tumor cell/T cell interactions. Ways that
this can be exploited include the use of cord blood ex-
panded immune cells [55,56], expansion of T cells ex
vivo, and development of tumor-specific T cells for
use as DLI. An exciting area is the use of T cells with
chimeric antigen receptors. T cells can be genetically
modified to recognize putative tumor-associated anti-
gens. In this regard, the receptor tyrosine kinase-like
orphan receptor 1 (ROR1) was identified as a highly
expressed gene in CLL, but not normal B cells, sug-
gesting it may serve as a tumor-specific target for ther-
apy. ROR1-specific CAR confer specific recognition
of primary B-CLL and MCL, including potential
tumor-initiating progenitor cells [57]. T cell therapies
targeting ROR1 may be effective in B-CLL and other
ROR1-positive tumors. However, the expression of
ROR1 on some normal tissues suggests the potential
for toxicity to subsets of normal cells.
CONCLUSIONS
SCT has a role to play in selected indolent lym-
phoma and CLL patients, with major focus on the
use of RIC allogeneic HSCT HSCT. Although RIC
HSCT HSCT appears to result in high response rates
and eradication of PCR detectable MRD, the follow-
up of most clinical trials is too short. However, it
does appear that RIC-SCT can cure these diseases.
Future approaches to the management of this disease
must take into account the balance between the
increased morbidity and mortality of HSCT with the
curative potential that these approaches potentially
offer, in the setting of the improvements in outcome
that can now be seen using chemoimmunotherapy.
In the absence of any other treatment modalities cur-
rently capable of improving outcome in this disease,
HSCT should be considered as a treatment approach
for younger patients with high-risk lymphoma earlier
in the course of the disease, ideally in the setting of
well-designed clinical trials assessing the impact of
this treatment on outcome in these patients and such
trials are currently underway.
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